**Supplementary table 1**. Clinical characteristics and species distribution for patients for whom isolates were referred for this study and for the remaining patients that were included in the clinical study.1

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Patients enrolled in *Candida* III with isolate(s) provided (n=385)** | **Patients enrolled in *Candida* III but no isolate(s) provided (n=247)** | **P (**Fisher's exact test) |
| **Enrolled by Tertiary Care Center** | 367 (95%) | 239 (97%) | 0.4187 |
| **Enrolled in Secondary Care** | 10 (3%) | 6 (2%) |  |
| **CRBSI#** | 71 (18%) | 59 (24%) | 0.1070 |
| **Risk factors for IC#** |  |  |  |
| ICU | 129 (34%) | 105 (43%) | **0.0230** |
| Haematological/Oncological malignancy | 142 (37%) | 105 (43%) | 0.1813 |
| **Causative *Candida* species\*** |  |  |  |
| Total *n* Isolates\* | 399 | 250 |  |
| *C. albicans* | 188 (47%) | 103 (42%) | 0.1452 |
| *C. glabrata* | 89 (22%) | 53 (21%) |  |
| *C. parapsilosis* | 60 (15%) | 33 (13%) |  |
| *C. tropicalis* | 25 (6.3%) | 21 (9%) | 0.3462 |
| *C. krusei* | 9 (2.3%) | 7 (3%) |  |
| *C. dubliniensis* | 9 (2.3%) | 3 (1%) |  |
| *C. lusitaniae* | 4 (1.0%) | 4 (2%) |  |
| *C. guilliermondii* | 3 (0.8%) | 3 (1%) |  |
| *C. kefyr* | 3 (0.8%) |  |  |
| *C. pelliculosa* | 2 (0.5%) |  |  |
| *C. inconspicua* | 2 (0.5%) |  |  |
| *C. auris* | 1 (0.3%) | 14 (6%)\*\* | **<0.0001** |
| *C. rugosa* | 1 (0.3%) | 2 (1%) |  |
| *C. digboiensis* | 1 (0.3%) |  |  |
| *C. haemulonii* | 1 (0.3%) |  |  |
| *C. orthopsilosis* | 1 (0.3%) |  |  |
| Not specified | 0 | 7 (3%) | **0.0012** |
| **#***Abbreviations: IC = invasive candidiasis;* CRBSI= Catheter Related Blood Stream Infection  \* some patients had more than one isolate  \*\* the 13 *C. auris* isolates not referred, all came from Russia, where they accounted for 37% of the 35 isolates. | | |  |

1 Hoenigl Martin, Salmanton-García Jon, Egger Matthias, Gangneux Jean-Pierre, Bicanic Tihana, Arikan-Akdagli Sevtap, et al. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. *Lancet Infect Dis* 2023;**23**(6):751–61. Doi: 10.1016/S1473-3099(22)00872-6.